A total of 186 neurotic patients seeking treatment in the psychiatry outpatient clinic of the Nehru Hospital, P.G.I.M.E.R. were assigned consequently to three treatments i.e. Yoga therapy (Y), Yogic Relaxation (YR) and Chemotherapy (C). A record was kept of the number of visits made by each patient during the 5 months study period. In order to find out the factors associated with treatment acceptance, a comparison was made of those subjects who completed 4-6 weeks of treatment with those who dropped out before completing the treatment in the yoga group. The dropouts and non-dropouts were found to be comparable on sociodemographic and clinical variables. They were also similar with regard to the attitude to yoga. The only factor which distinguished the two groups was the severity of illness at intake. Those who continued treatment had significantly higher scores on the P. G. I. Health Questionnaire N-2 and the clinical ratings of the severity of illness. Further, analysis of stage at which dropout occurred, and the responses to the reply paid questionnaire indicated that treatment failure as not the main reason for dropout.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992123PMC

Publication Analysis

Top Keywords

treatment acceptance
8
neurotic patients
8
severity illness
8
treatment
7
factors influencing
4
influencing treatment
4
acceptance neurotic
4
patients referred
4
yoga
4
referred yoga
4

Similar Publications

Background: Stigma is a pervasive and distressing problem experienced frequently by lung cancer patients, and there is a lack of psychosocial interventions that target the reduction of lung cancer stigma. Mindful self-compassion (MSC) is an empirically supported intervention demonstrated to increase self-compassion and reduce feelings of shame and distress in non-cancer populations. However, there are several anticipated challenges for delivering MSC to lung cancer patients, and modifications may be needed to improve acceptability, appropriateness, and feasibility.

View Article and Find Full Text PDF

Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.

Liver Int

February 2025

APHP, Hôpital Paul-Brousse, Centre Hépato-Biliaire, Inserm, Unité 1193, Université Paris-Saclay, FHU Hepatinov, Villejuif, France.

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer, though they come with the risk of immune-related adverse (irAEs) events such as hepatotoxicity or Immune-mediated Liver Injury from Checkpoint Inhibitors (ILICI). ILICI is a serious irAE that, when severe, requires cessation of ICI and initiation of immunosuppression. Cytotoxic T Lymphocytes (CTLs) play a central role in ILICI; however, they are just part of the picture as immunotherapy broadly impacts all aspects of the immune microenvironment and can directly and indirectly activate innate and adaptive immune cells.

View Article and Find Full Text PDF

Objectives: Placebo effects can relieve acute and chronic pain in both research and clinical treatments by learning mechanisms. However, the application of placebo-based treatment strategies in routine medical care is questioned. The current study investigated the opinions of patients with fibromyalgia and healthy controls regarding learning of placebo effects and their practical applications.

View Article and Find Full Text PDF

Objectives: To report the management and outcomes of five horses with ear skin defects treated with the use of full-thickness mesh grafts and full-thickness Meek micrografts.

Animals: Five horses with acute or granulating pinna skin wounds.

Study Design: Short case series.

View Article and Find Full Text PDF

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

Hum Vaccin Immunother

December 2025

Crucell Integration, Janssen Research and Development, Beerse, Belgium.

We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10 viral particles [vp]) in healthy adolescents aged 12-17 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!